摘要
目的:比较米卡芬净和伊曲康唑治疗肺部侵袭性真菌感染(IPFI)的临床疗效。方法:将本院2007年1月～2010年2月收治的80例IPFI患者按照治疗方法不同分为米卡芬净组和伊曲康唑组,米卡芬净组38例,伊曲康唑组42例,15d为1个疗程,两组均治疗2个疗程后,比较临床疗效和不良反应的发生情况,并进行统计分析。结果:伊曲康唑组愈显率和总有效率均明显高于米卡芬净组,两组比较,差异有统计学意义(P<0.05);两组不良反应比较无统计学意义(P>0.05)。结论:伊曲康唑治疗肺部侵袭性真菌感染疗效确切,副作用小,值得推广使用。
Objective：To compare clinical efficacy of micafungin and itraconazole treatment of pulmonary invasive fungal infections（IPFI）.Methods：80 patients in our hospital from January 2007 to February 2010 were divided into micafungin group and itraconazole group according to the different treatment methods,micafungin group 38 cases,itraconazole group 42 cases,15 days for a course of treatment,after two courses compared the clinical efficacy and the incidence of adverse reactions,and make statistical analysis.Results：Itraconazole group markedly effective rate and total effective rate was significantly higher than the micafungin group,two groups were significant different（P0.05）,difference of adverse reactions the was not significant between two groups（P0.05）.Conclusion：Itraconazole treatment of pulmonary invasive fungal infections is effective,side-effect is small,it should be promoted.
出处
《中国当代医药》
2010年第36期33-34,共2页
China Modern Medicine
